Alopecia Treatment Global Market Report 2025

The alopecia treatment market size has grown strongly in recent years. It will grow from $9.56 billion in 2024 to $10.22 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historical period can be attributed to the rising prevalence of alopecia, an aging population, hormonal changes, genetic factors, increased awareness of hair loss treatments, expansion of the cosmetic and dermatology industries, and better access to healthcare.

The alopecia treatment market size is expected to see strong growth in the next few years. It will grow to $13.22 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth during the forecast period can be attributed to the rising adoption of non-invasive treatments, increasing demand for personalized medicine, a growing focus on mental health and self-esteem, greater consumer awareness of hair loss causes and treatments, and a rise in clinical trials for alopecia therapies. Key trends in the forecast period include advancements in stem cell-based hair regeneration, the use of platelet-rich plasma (PRP) therapy, the development of JAK inhibitors for autoimmune-related alopecia, innovations in laser hair therapy, and the emergence of wearable devices for stimulating hair growth.

The growing prevalence of hair loss is expected to accelerate the growth of the alopecia treatment market. Hair loss refers to the condition in which an individual experiences partial or complete hair loss from the scalp or other areas of the body. The prevalence of hair loss is rising due to factors such as elevated stress levels, which can disrupt the normal hair growth cycle and trigger conditions including telogen effluvium, resulting in excessive hair shedding. As more individuals seek effective solutions to manage and reverse hair loss, the demand for advanced and accessible alopecia treatments is increasing. For example, in October 2024, the American Academy of Dermatology, a U.S.-based professional medical association specializing in dermatology, reported that 80 million Americans were affected by hair loss, including 50 million men and 30 million women. Thus, the growing prevalence of hair loss is fueling the expansion of the alopecia treatment market.

Leading companies in the alopecia treatment market are focusing on developing innovative solutions, such as oral small-molecule Janus kinase (JAK) inhibitors, to improve treatment efficacy, accelerate hair regrowth, and provide targeted therapy for patients with severe or resistant forms of alopecia areata. Oral small-molecule JAK inhibitors are a class of targeted pharmaceutical drugs designed to block the activity of one or more Janus kinase enzymes (JAK1, JAK2, JAK3, and TYK2). For example, in July 2024, Sun Pharmaceutical Industries Limited, a pharmaceutical company based in India, received approval from the U.S. Food and Drug Administration (FDA) for LEQSELVI, an oral JAK inhibitor, for the treatment of adults with severe alopecia areata. LEQSELVI selectively inhibits the JAK1 and JAK2 enzymes, which play a key role in the immune system's attack on hair follicles in this autoimmune disorder. The recommended dosage is 8 mg orally twice daily, with or without food. This FDA approval introduces a new, effective treatment option for individuals suffering from alopecia areata, a condition that can have significant physical, emotional, and social effects.

In February 2023, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Concert Pharmaceuticals for $576 million. This acquisition provided Sun Pharma with access to deuruxolitinib, a late-stage oral JAK inhibitor being developed for the treatment of alopecia areata. The move strengthens Sun Pharma’s dermatology portfolio and bolsters its position in the global specialty pharmaceuticals market. Concert Pharmaceuticals Inc. is a US-based biopharmaceutical company, specializing in developing novel small-molecule drugs for treating alopecia areata.

Major players in the alopecia treatment market are Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Inc., Incyte Corporation, Hims & Hers Health Inc., Bosley Inc., Hair Club Co., Dermavant Sciences Inc., Histogen Inc., Capillus llc, Aclaris Therapeutics Inc., Nutrafol, Alvi Armani Co, Rogaine, Theradome Inc., Viviscal Ltd, Arena Pharmaceuticals Ltd, Cassiopea SA, Follica Inc., RepliCel Life Sciences Inc., HairClone Ltd, Revian Inc., and Nioxin.

North America was the largest region in the alopecia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in alopecia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alopecia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alopecia treatment encompasses a range of medical and cosmetic methods aimed at managing and reducing hair loss, and in some cases, encouraging hair regrowth. Treatment options include topical solutions including minoxidil, oral medications, steroid injections, and therapies targeting the immune system. The choice of treatment depends on the type and severity of alopecia.

The primary treatment forms in the alopecia market include drug therapy, hair transplant services, and low-level laser therapy. Drug therapies include both prescription and over-the-counter pharmaceutical treatments that address hair loss through various mechanisms. These treatments can be administered through different routes, such as topical applications and injections, and are used for conditions including alopecia areata, alopecia totalis, alopecia universalis, alopecia barbae, chemotherapy-induced alopecia, and others. The treatments are available for both males and females. Key end users of these treatments include hospitals, physician offices, dermatology clinics, and other healthcare facilities.

The alopecia treatment market research report is one of a series of new reports that provides alopecia treatment market statistics, including alopecia treatment industry global market size, regional shares, competitors with a alopecia treatment market share, detailed alopecia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alopecia treatment industry. The alopecia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alopecia treatment market consists of revenues earned by entities providing a wide range of services, such as medical consultations, hair restoration procedures, topical and oral medications, laser therapies, and personalized treatment plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The alopecia treatment market also includes sales of products such as topical solutions, oral medications, hair growth shampoos, and laser therapy devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.